Canada markets closed


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
43.28+0.58 (+1.37%)
At close: 4:00PM EST


9600 Blackwell Road
Suite 210
Rockville, MD 20850
United States
240 552 8181

Full Time Employees257

Key Executives

NameTitlePayExercisedYear Born
Mr. Kenneth T. MillsCEO, Pres & Director986.83k7.14M1975
Mr. Vittal K. VasistaChief Financial Officer636.48k5.1M1968
Mr. Patrick J. Christmas IIChief Legal Officer610.82k701.5k1971
Dr. Olivier DanosChief Scientific Officer622.73k250.31k1958
Dr. Stephen PakolaChief Medical Officer549.77kN/A1969
Mr. Curran M. Simpson M.S.Chief Operations & Technology OfficerN/AN/A1962
Ms. Tricia TruehartVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Andrew YostVP of Corp. Devel.N/AN/AN/A
Ms. Shiva G. FritschChief People OfficerN/AN/AN/A
Dr. Laura A. CoruzziSr. VP of Intellectual PropertyN/AN/A1953
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Corporate Governance

REGENXBIO Inc.’s ISS Governance QualityScore as of January 22, 2021 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.